Boyds, MD, United States of America

Michael Mesa

This inventor holds 7 USPTO granted patents and 5 published patent applications. Top assignee: Bryn Pharma, LLC. Active years: 2020-2025.

USPTO Granted Patents = 7 

% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 3

Forward Citations = 33(Granted Patents)


Company Filing History:


Years Active: 2020-2025

Loading Chart...
7 patents (USPTO):Explore Patents

Title: Michael Mesa: Innovator in Epinephrine Spray Formulations

Introduction

Michael Mesa is a notable inventor based in Boyds, MD (US), recognized for his contributions to the field of medical formulations. With a total of 7 patents to his name, he has made significant strides in developing innovative solutions for treating anaphylaxis.

Latest Patents

Among his latest patents, Michael has focused on epinephrine spray formulations. These formulations are designed to provide effective treatment for individuals experiencing anaphylaxis. The methods he has developed involve administering these epinephrine spray formulations to subjects in need of such treatment, showcasing his commitment to improving patient care.

Career Highlights

Michael Mesa currently works at Bryn Pharma, LLC, where he continues to advance his research and development efforts. His work at Bryn Pharma emphasizes the importance of innovation in the pharmaceutical industry, particularly in emergency medical treatments.

Collaborations

Michael collaborates with talented professionals in his field, including Steven Hartman and Michelle Lobel. Their combined expertise contributes to the success of their projects and the advancement of medical technologies.

Conclusion

Michael Mesa's innovative work in epinephrine spray formulations highlights his dedication to improving medical treatments for anaphylaxis. His contributions to the field are invaluable and reflect the importance of ongoing research and development in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…